These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 35953195)
21. Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells. Bolton-Gillespie E; Schemionek M; Klein HU; Flis S; Hoser G; Lange T; Nieborowska-Skorska M; Maier J; Kerstiens L; Koptyra M; Müller MC; Modi H; Stoklosa T; Seferynska I; Bhatia R; Holyoake TL; Koschmieder S; Skorski T Blood; 2013 May; 121(20):4175-83. PubMed ID: 23543457 [TBL] [Abstract][Full Text] [Related]
22. Lipopolymer mediated siRNA delivery targeting aberrant oncogenes for effective therapy of myeloid leukemia in preclinical animal models. Ansari AS; K C R; Morales LC; Nasrullah M; Meenakshi Sundaram DN; Kucharski C; Jiang X; Brandwein J; Uludağ H J Control Release; 2024 Mar; 367():821-836. PubMed ID: 38360178 [TBL] [Abstract][Full Text] [Related]
23. Loss of the vitamin D receptor triggers senescence in chronic myeloid leukemia via DDIT4-mediated DNA damage. Xu Y; Qi W; Zheng C; Li Y; Lu Z; Guan J; Lu C; Zhao B J Mol Cell Biol; 2024 Apr; 15(10):. PubMed ID: 37880985 [TBL] [Abstract][Full Text] [Related]
24. Efficacy of tyrosine kinase inhibitors on a mouse chronic myeloid leukemia model and chronic myeloid leukemia stem cells. Tanaka Y; Fukushima T; Mikami K; Adachi K; Fukuyama T; Goyama S; Kitamura T Exp Hematol; 2020 Oct; 90():46-51.e2. PubMed ID: 32910995 [TBL] [Abstract][Full Text] [Related]
25. Eliminating chronic myeloid leukemia stem cells by IRAK1/4 inhibitors. Tanaka Y; Takeda R; Fukushima T; Mikami K; Tsuchiya S; Tamura M; Adachi K; Umemoto T; Asada S; Watanabe N; Morishita S; Imai M; Nagata M; Araki M; Takizawa H; Fukuyama T; Lamagna C; Masuda ES; Ito R; Goyama S; Komatsu N; Takaku T; Kitamura T Nat Commun; 2022 Jan; 13(1):271. PubMed ID: 35022428 [TBL] [Abstract][Full Text] [Related]
27. Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia. Gleixner KV; Schneeweiss M; Eisenwort G; Berger D; Herrmann H; Blatt K; Greiner G; Byrgazov K; Hoermann G; Konopleva M; Waliul I; Cumaraswamy AA; Gunning PT; Maeda H; Moriggl R; Deininger M; Lion T; Andreeff M; Valent P Haematologica; 2017 Sep; 102(9):1519-1529. PubMed ID: 28596283 [TBL] [Abstract][Full Text] [Related]
28. BCR-ABL1 mediated miR-150 downregulation through MYC contributed to myeloid differentiation block and drug resistance in chronic myeloid leukemia. Srutova K; Curik N; Burda P; Savvulidi F; Silvestri G; Trotta R; Klamova H; Pecherkova P; Sovova Z; Koblihova J; Stopka T; Perrotti D; Polakova KM Haematologica; 2018 Dec; 103(12):2016-2025. PubMed ID: 30049824 [TBL] [Abstract][Full Text] [Related]
29. Targeting Leukemic Stem Cells in Chronic Myeloid Leukemia: Is It Worth the Effort? Soverini S; De Santis S; Monaldi C; Bruno S; Mancini M Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34209376 [TBL] [Abstract][Full Text] [Related]
30. Molecular mechanisms for survival regulation of chronic myeloid leukemia stem cells. Zhang H; Li S Protein Cell; 2013 Mar; 4(3):186-96. PubMed ID: 23483480 [TBL] [Abstract][Full Text] [Related]
31. Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy. Ali MA Mol Diagn Ther; 2016 Aug; 20(4):315-33. PubMed ID: 27220498 [TBL] [Abstract][Full Text] [Related]
32. Antitumor Effects of Blocking Protein Neddylation in T315I-BCR-ABL Leukemia Cells and Leukemia Stem Cells. Liu C; Nie D; Li J; Du X; Lu Y; Li Y; Zhou J; Jin Y; Pan J Cancer Res; 2018 Mar; 78(6):1522-1536. PubMed ID: 29321163 [TBL] [Abstract][Full Text] [Related]
34. Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells. Carter BZ; Mak PY; Mu H; Zhou H; Mak DH; Schober W; Leverson JD; Zhang B; Bhatia R; Huang X; Cortes J; Kantarjian H; Konopleva M; Andreeff M Sci Transl Med; 2016 Sep; 8(355):355ra117. PubMed ID: 27605552 [TBL] [Abstract][Full Text] [Related]
35. The Impact of Tyrosine Kinase Inhibitors on Chronic Myeloid Leukemia Stem Cells and the Implication in Discontinuation. Jiang L; Wang H; Zhu X; Liu W; Zhou S; Geng Z; Xiao Y; Zou P; You Y; Li Q; Zhu X Stem Cells Dev; 2019 Nov; 28(22):1480-1485. PubMed ID: 31530245 [TBL] [Abstract][Full Text] [Related]
36. Chronic myeloid leukemia stem cells and molecular target therapies for overcoming resistance and disease persistence. Inoue A; Kobayashi CI; Shinohara H; Miyamoto K; Yamauchi N; Yuda J; Akao Y; Minami Y Int J Hematol; 2018 Oct; 108(4):365-370. PubMed ID: 30155588 [TBL] [Abstract][Full Text] [Related]